The following article was published in Australian Doctor: www.australiandoctor.com.au by Dr Nicholas CL Chin.
Endobronchial valve therapy offers a new, non-surgical option for patients with COPD.
COPD is a debilitating pulmonary disease characterised by abnormal and permanent dilatation of airspace distal to the terminal bronchioles.
The resultant gradual destruction of the alveolar walls impairs gas exchange, leading to progressive gas trapping, and subsequent deterioration in pulmonary function, exercise capacity and quality of life.
In the early 1990s, the surgical technique of lung volume reduction was found to improve respiratory function, exercise tolerance, quality of life and survival in selected patients with heterogeneous, predominantly upper lobe COPD.
Many of these findings emerged from the National Emphysema Treatment Trial (NETT) in the US.
However, as well as these benefits, data from the NETT showed a high risk of death among patients with very low forced expiratory volume (FEV1 less than or equal to 20% of predicted), low diffusing capacity of the lung for carbon monoxide (DLCO less than or equal to 20% of predicted) and a homogeneous pattern of COPD.
And post-operative care frequently involved an ICU stay because of prolonged air leak. In some patients, the procedure was associated with significant risk of morbidity without attaining clinical improvement.
All these factors have resulted in the exclusion of most patients with severe COPD from lung volume reduction surgery.
Over the past decade, the technique of bronchoscopic treatment of COPD has emerged as a safer and more cost-effective alternative.
Various bronchoscopic lung volume reduction techniques have been described, including radiofrequency fenestration of the bronchial wall with stent placement, umbrella blockers, and injection of fibrin glue.
Endobronchial plugs and blockers were the initial methods adopted, but later abandoned due to the high risk of postobstructive pneumonia and device migration.
More recently, endobronchial valve therapy has re-emerged with the development and utilisation of one-way endobronchial (Zephyr, left) and intrabronchial (Spiration, right) valves (pictured below).
These are novel, implantable one-way valves that are deployed into targeted bronchopulmonary segments via flexible bronchoscopy.
Their goal is to achieve complete atelectasis of a segment of hyperinflated lung, which is commonly seen in severe COPD, thus mimicking the physiological changes of lung volume reduction surgery (see below).
Patient selection for endobronchial valve therapy
Patient assessment is of utmost importance in ensuring treatment success.
It is recommended that all COPD patients who have significant ongoing symptoms, despite optimal medication and completion of pulmonary rehabilitation, should be referred to a respiratory physician for consideration of endobronchial valve therapy, especially if they have FEV1 of 15-45% predicted, and residual volume of greater than180% predicted.
Patients who meet these criteria will be further assessed for the heterogeneity of their disease, and for fissure integrity with high-resolution computer tomography of the chest, quantitative ventilation and the presence of collateral ventilation.
Role of computer tomography in predicting success
The utilisation of high-resolution computer tomography assessment pre- and post-procedure has significantly improved the success rate of endobronchial valve therapy.
The presence of complete fissure integrity tends to be associated with higher improvements in FEV1 and higher scores in the St George’s Respiratory Questionnaire, than with other subgroups, at 6-12 months.
One of the other major limitations to successful endobronchial valve therapy is the presence of collateral ventilation. Collateral ventilation is defined as the ventilation of alveolar structures through passages or channels that bypass the normal airways.
The additional valve deployment to the adjacent ipsilateral lobe will thus be required to artificially close the ventilation loop and ultimately achieve complete atelectasis.
A recent study demonstrated that Chartis Pulmonary Assessment System (pictured below) could predict with 75% accuracy which patients would obtain significant clinical response to valve therapy.
Improvement in pulmonary function tests
Studies have shown improvement in forced vital capacity (FVC) at 90 days, reduction in residual volume (RV) at 30 and at 90 days, as well as improvement in DLCO at four weeks.
The Six-Minute Walk Test
Four studies recorded an improvement in the Six-Minute Walk Test, with Herth et al describing an average improvement of 15m among its subjects.
Quality of life improvement
Five studies have independently recorded an improvement in patients’ quality of life following valve therapy.
In the VENT studies, there was up to five units improvement in the St George’s Respiratory Questionnaire at six months. This benefit was similarly observed at 12 months post valve insertion.
The questionnaire consists of 50 questions, and is designed to measure impact on overall health, daily life and perceived wellbeing of patients with COPD. A mean change score of four units is associated with slightly efficacious treatment.
The majority of valve recipients experience no complications. The most common complications associated with this procedure are COPD exacerbations and non-valve pneumonia.
The more serious, but uncommon, complications include pneumothorax, with or without prolonged air leak, valve migration and/or expectoration, post-obstructive pneumonia, and/or empyema and massive haemoptysis.
This is a marked advantage compared with the overall higher perioperative mortality rate of lung volume reduction surgery, with the most common complication, prolonged air leak, alone approaching 40%.
Although many studies have adopted the National Emphysema Treatment Trial inclusion/exclusion criteria to exclude patients with more severe disease, bronchoscopic lung volume valve reduction is minimally invasive and is better tolerated than surgical lung volume reduction.
It is also relatively cost-effective compared with its surgical counterpart, in terms of product cost, procedure time and the skilled expertise required.
Currently in Australia, endobronchial valve insertion is approved by the TGA and has been assigned an MBS item number. However, it is not yet subsidised by the PBS, and so is only accessible privately.
Endobronchial valve therapy is an emerging technique in the management of severe COPD.
In carefully selected patients with end-stage COPD, it is effective in improving pulmonary function, exercise capacity and the quality of life of patients not responding to conventional medication and pulmonary rehabilitation. It is a relatively safe and cost-effective procedure, particularly when compared with lung volume reduction surgery.
Dr Chin is a specialist in both general medicine and respiratory medicine. He practises with Eastern Health and consults in Melbourne, Victoria.
References on request.
Share this entry